What is Nordson's gross profit margin?

What guidance did Nordson's management provide for the next earnings period?

What is the revenue and EPS growth rate for Nordson year over year?

What is the market's earnings forecast for Nordson next quarter?

What is Nordson's latest dividend and current dividend yield?

What were the key takeaways from Nordson's earnings call?

What were the key takeaways from Nordson’s earnings call?

What does Nordson do and what are its main business segments?

- **Record Financial Performance**: Q4 2025 EBITDA of $256M (34% margin) and FY2025 EBITDA of $900M (32% margin), exceeding 2025 Ascend Strategy goals. 
- **Strong Cash Generation**: Free cash flow of $661M in FY2025, enabling $300M share buybacks and dividend increases. 
- **Medical Segment Strength**: Medical & Fluid Solutions EBITDA up 21% YoY to $88M (40% margin), driven by Atrion integration and destocking recovery. 
- **Semiconductor Growth**: 50% of ATS revenue tied to semiconductors, with AI and cloud-driven demand offsetting automotive weakness. 
- **2026 Guidance**: Sales growth 1-6% (midpoint 3.5%), adjusted EPS growth 6-12% (midpoint 9%), reflecting balanced organic and acquisitive growth strategy. 
- **Leverage Optimization**: Net debt reduced to $1.9B (2.1x leverage), positioning for continued shareholder returns. 

**【CEO Summary Section】**
- **Q4 2025 Results**: Sales grew 1% YoY to $752M, with adjusted EPS up 9% to $3.03, beating guidance. Record EBITDA of $256M (34% margin) and free cash flow of $194M (128% net income conversion). 
- **FY2025 Highlights**: Record sales of $2.8B (+4% YoY), adjusted EPS of $10.24 (+5%), and EBITDA of $900M (32% margin). Divestiture of medical contract manufacturing improved margins and focus on core medical businesses. 
- **Ascend Strategy Progress**: Achieved 2025 EBITDA target of $900M, with 5-year EBITDA CAGR of 10%. Free cash flow conversion of 136% enabled $300M share buybacks and dividend increases. 
- **2026 Outlook**: Sales guidance of 1-6% growth (midpoint 3.5%), adjusted EPS growth of 6-12% (midpoint 9%). Q1 2026 sales expected $630-670M, EPS $2.25-2.45. 

**【CFO Financial Commentary】**
- **Q4 Segment Performance**: 
  - **Medical & Fluid Solutions**: Sales +10% YoY ($220M), EBITDA +21% to $88M (40% margin), driven by destocking recovery and Atrion integration. 
  - **Industrial Precision Solutions**: Sales -2% YoY ($362M), EBITDA $137M (38% margin), with stabilization in polymer processing and coating systems. 
  - **Advanced Technology Solutions**: Sales -4% YoY ($171M), EBITDA $43M (25% margin), impacted by X-ray systems weakness but strong semiconductor end market exposure. 
- **Full Year Metrics**: GAAP EPS $8.51, free cash flow $661M, and net debt reduced to $1.9B (2.1x leverage). 
- **2026 Financial Assumptions**: Tax rate 18.5-19.5%, capex $55-65M, interest expense $85-95M. 

**【Q&A Highlights】**
- **Semiconductor Growth**: 50% of ATS revenue tied to semiconductors, with AI and cloud-driven demand offsetting automotive weakness. X-ray systems expected to recover with new product launches. 
- **Margin Trajectory**: Medical margins sustainable at upper 30s, IPS and ATS margins aligning with historical performance. 
- **Backlog & Execution**: FY2026 backlog up 5% YoY, with Q1 2026 sales growth driven by favorable comps and stable demand. 
- **M&A Strategy**: Balanced approach to share buybacks and high-quality acquisitions, with $250M+ stock price viewed as attractive for returns. 
- **Risk Management**: Guidance range accounts for macroeconomic uncertainty, with Q4 2025 results showing operational resilience. 

Nordson Corporation(NDSN)-20251211-2025 Q4 Earnings call transcript

- **Revenue Growth**: Q3 2025 revenue $742 million (+12% YoY), driven by Atrion (+8%) and ATS (+17% organic). Adjusted EPS $2.73 (+13% YoY).
- **Cash Flow Strength**: Record free cash flow $226 million (180% of net income). Share buybacks $212 million YTD, new $500 million authorization.
- **Segment Performance**: ATS leads with 17% growth, MFS benefits from Atrion, IPS stabilizes after trough in plastics.
- **Margins & Efficiency**: EBITDA margin 32% (+70bps YoY). Restructuring to save $15 million annually by 2026.
- **Strategic Moves**: Atrion integration ahead of schedule, disciplined M&A, balanced capital allocation.

**【CEO Summary Section】**
- Q3 2025 revenue of $742 million (+12% YoY), above midpoint of guidance, driven by 8% contribution from Atrion acquisition. Advanced Technology Solutions (ATS) segment delivered 17% organic growth, second consecutive quarter of double-digit growth.
- Adjusted EPS of $2.73 (+13% YoY), EBITDA of $239 million (+15% YoY). Free cash flow of $226 million (180% of net income), record quarterly level.
- Share repurchases of $70 million in Q3, total $212 million YTD. New $500 million buyback authorization approved, total remaining $800 million.
- Atrion integration ahead of schedule, contributing to EPS accretion a year earlier than expected. Restructuring actions to save $15 million annually by 2026.

**【CFO Financial Commentary】**
- Total sales: $742 million (+12% YoY). Organic growth 2% (3% excluding medical contract manufacturing). Currency impact +2%.
- Gross margin 55%, stable. SG&A leverage improved, operating profit +15% YoY. EBITDA margin 32% (+70bps YoY).
- Net income $126 million ($2.22 EPS). Adjusted EPS $2.73 (+13% YoY). Tax rate 19% (adjusted basis).
- Segment performance:
  - Industrial Precision Solutions (IPS): $351 million (+1% YoY). Organic -2%, offset by +3% currency. EBITDA 37%.
  - Medical & Fluid Solutions (MFS): $219 million (+32% YoY). Atrion contributed $52 million. Organic +4% (excluding divestiture). EBITDA 38%.
  - ATS: $171 million (+17% YoY). Organic +15%. EBITDA 24% (+35% YoY).
- Cash flow: $148 million on hand, net debt $2 billion. Leverage ratio 2.2x (down from 2.5x start of year).

**【Q&A Key Highlights】**
- **Order Momentum**: 
  - ATS: Strong demand in semiconductor packaging, electronics. Sequential growth expected, but lumpy. Q3 backlog decline due to strong shipments.
  - Medical: Fluid components +4% organic (excluding divestiture). Interventional solutions normalized after destocking.
  - IPS: Packaging, nonwoven, precision ag strong. Plastics business bottoming out.
- **Tariffs & Trade**: Dynamic environment, but no direct evidence of customer pull-ahead. Order entry stable.
- **M&A**: Pipeline healthy, disciplined approach. Atrion success story (EPS accretive 1 year ahead of schedule).
- **Divestiture**: Medical contract manufacturing divestiture expected Q4. Charge $12.2 million (fair value write-down, restructuring).
- **ATS Margins**: 24-25% EBITDA margin at current run rate. Incremental margins better than company average due to new product investments (14-15% of revenue).


Nordson Corporation (NDSN) Q3 2025 Earnings Conference Call Transcript

- **Q2 Revenue Beats Expectations**: $683M (+5% YoY), driven by 18% growth in ATS and 20% expansion in MFS.
- **Profit Margin Expansion**: EBITDA margin improved to 32%, with ATS EBITDA up 43% YoY and MFS margin at 38%.
- **Strategic Divestiture**: Medical contract manufacturing sale to Quasar expected to boost MFS margins by 100bps post-closing.
- **Operational Efficiency**: $50M+ annual cost savings from restructuring, supporting sequential improvement in industrial systems.
- **Investment in Growth**: $141M in share buybacks YTD and $16M in capex for new manufacturing facilities in SC and India.

**【CEO Opening Remarks】**
- Q2 revenue of $683M (+5% YoY), driven by Atrion acquisition (+8%) and strong performance in Advanced Technology Systems (ATS) (+18% YoY). Medical & Fluid Solutions (MFS) grew 20% due to Atrion and fluid components recovery.
- Gross margin remained stable at 55%, with EBITDA margin improving to 32% (vs. 30% prior year), driven by operational efficiency and Atrion's contribution.
- Share buybacks of $85M and dividend payments of $44M maintained financial flexibility, with leverage ratio at 2.4x (target 2.0-2.5x).

**【CFO Financial Breakdown】**
- **ATS Segment**: Sales $161M (+18% YoY), EBITDA $40M (25% margin), up 43% YoY due to demand in electronics dispense and x-ray inspection systems.
- **MFS Segment**: Sales $203M (+20% YoY), EBITDA $77M (38% margin), benefiting from Atrion's $51M contribution and destocking trends easing.
- **IPS Segment**: Sales $319M (-8% YoY), EBITDA $114M (36% margin), impacted by weak industrial coatings and polymer processing markets.
- Free cash flow of $103M (92% of net income), with $141M in total share buybacks YTD.

**【CEO Strategic Updates】**
- Announced divestiture of low-margin medical contract manufacturing business, expected to close Q4 2025 and improve MFS margins by ~100bps.
- Implemented restructuring to reduce costs by $50M+ annually by FY26, targeting sequential improvement in industrial systems.
- Expanded manufacturing in South Carolina (industrial coatings) and India (electronics solutions) to support regional demand.

**【Q&A Highlights】**
- **ATS Growth**: 5%+ organic growth expected long-term, with Q3 order momentum supporting semiconductor and AI investments.
- **MFS Recovery**: Destocking in interventional devices nearing end; fluid components growth and Atrion driving MFS expansion.
- **Tariff Mitigation**: 85-90% of sales covered by in-region manufacturing; minor price adjustments offset remaining costs.
- **Share Buybacks**: Prioritized over debt reduction in Q2, with $141M spent YTD to date.


Nordson Corporation (NDSN) Q2 2025 Earnings Call Transcript

- **Resilient Q1 Performance:** $615M sales (low end of guidance) driven by Atrion (+$53M) and consumer non-durables, despite 9% organic decline.
- **Order Momentum:** Backlog up $85M to $670M, with double-digit growth in ATS and electronics order entry.
- **Profitability Strength:** 56% gross margin, 31% EBITDA margin, $2.06 adj. EPS (slightly above midpoint).
- **Medical Growth Catalyst:** Atrion outperforming expectations; interventional med destocking to abate Q3.
- **Leverage Management:** Net debt $2.1B (2.4x leverage), $138M free cash flow, $60M buybacks.
- **Guidance Confidence:** Despite slow start, maintain FY2025 EPS guidance based on strong operational execution and backlog conversion.

**【CEO Opening Remarks】**
- Q1 FY2025 sales of $615M, at the low end of guidance due to soft demand in electronics and industrial markets, partially offset by Atrion acquisition and consumer non-durables growth.
- Order entry accelerated 10%+ YoY, with backlog increasing $85M to $670M, driven by electronics recovery.
- Strong operational performance: 56% gross margin, 31% EBITDA margin, $2.06 adj. EPS (slightly above midpoint of guidance).
- Capital deployment: $60M share buybacks, $45M dividends, net leverage 2.4x (target range 2.0-2.5x).

**【CFO Financial Review】**
- **Industrial Precision Solutions (IPS):**
  - Sales $300M (-8% organic, -3% FX), EBITDA $113M (38% margin).
  - Packaging and nonwovens offset industrial coatings decline; South Carolina plant transition nearing completion.
- **Medical & Fluid Solutions (MFS):**
  - Sales $194M (+21% driven by Atrion), EBITDA $64M (33% margin).
  - Atrion outperformed expectations; interventional med destocking expected to abate Q3/Q4.
- **Advanced Technology Solutions (ATS):**
  - Sales $121M (-11% organic), EBITDA $23M (19% margin).
  - Electronics order entry up double digits; SpinSAM and QuadraPro products recognized with industry awards.
- **Balance Sheet & Cash Flow:**
  - Free cash flow $138M (146% of net income), $20M net debt reduction, $21M capex spent.

**【Q&A Key Takeaways】**
- **Electronics Recovery:**
  - ATS order entry up double digits, backlog growth strongest in cycle; expect sequential improvement.
  - X-ray and electronic processing timing delays, but long-term demand trends positive.
- **Medical Business:**
  - Atrion margin improving sequentially; core MFS decrementals strong despite Atrion mix drag.
  - Interventional med destocking to complete Q2, sequential growth expected Q3+.
- **Market Outlook:**
  - FY2025 sales likely at lower end of range due to slow start; confident in ability to deliver EPS guidance despite lower sales.
  - Strong backlog ($670M) and order trends position for recovery in key markets.
  - Incremental margin target 35% (30% organic, 40% inorganic) remains valid.


NDSN

NDSN fundamentals

Earnings Call

You can ask Aime